<DOC>
	<DOCNO>NCT02951130</DOCNO>
	<brief_summary>Infants congenital diaphragmatic hernia ( CDH ) usually pulmonary hypoplasia persistent pulmonary hypertension newborn ( PPHN ) lead hypoxemic respiratory failure ( HRF ) . Pulmonary hypertension associate CDH frequently resistant conventional pulmonary vasodilator therapy include inhaled nitric oxide ( iNO ) . Increased pulmonary vascular resistance ( PVR ) lead right ventricular overload dysfunction . In patient CDH , leave ventricular dysfunction , either cause right ventricular overload relative underdevelopment leave ventricle , associate poor prognosis . Milrinone intravenous inotrope lusitrope ( enhances cardiac systolic contraction diastolic relaxation respectively ) pulmonary vasodilator property show anecdotally improve oxygenation PPHN . Milrinone commonly use management CDH although randomize trial perform test efficacy . Thirty percent infant CDH Children 's Hospital Neonatal Database ( CHND ) 22 % late-preterm term infant CDH Pediatrix database receive milrinone . In recently publish VICI trial , 84 % patient CDH receive vasoactive medication . In current pilot trial , neonates antenatal postnatal diagnosis CDH randomize receive milrinone placebo establish safety medication CDH test efficacy improve oxygenation .</brief_summary>
	<brief_title>Milrinone Congenital Diaphragmatic Hernia</brief_title>
	<detailed_description>This pilot trial determine milrinone infusion neonates ≥ 36 week ' postmenstrual age ( PMA ) birth CDH would lead increase PaO2 correspond decrease OI conjunction pulmonary vasodilator iNO 24 h post-infusion .</detailed_description>
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Hernia , Diaphragmatic</mesh_term>
	<mesh_term>Hernias , Diaphragmatic , Congenital</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Milrinone</mesh_term>
	<criteria>Eligibility criterion : Infants eligible meet follow criterion : ≥ 36 0/7 week PMA best obstetric estimate AND birth weight ≥ 2000g postnatal age ≤7 day ( 168 hour age ) invasive mechanical ventilation ( defined ventilation endotracheal tube ) one arterial blood gas OI ≥ 10 ( tracheal tube obstruction easily resolvable mechanical cause increase OI rule ) recent arterial blood gas within 12 hour prior time randomization . arterial blood gas available time randomization , preductal OSI ≥ 5 use inclusion criterion instead OI ≥ 10 ; ( OSI base recent preductal pulse oximetry record must within 12 hour randomization ) postnatal blood gas PCO2 ≤ 80 mmHg ( arterial , capillary venous blood gas ) recent blood gas sample obtain within 12 hour prior randomization Note : Criteria ( iv ) ( vi ) must meet recent analysis within 12 hour prior randomization . Infants ineligible meet follow criterion : know hypertrophic cardiomyopathy Note 1 : infant diabetic mother asymmetric septal hypertrophy include long evidence obstruction leave ventricular outflow tract echocardiogram , Note 2 : infant acyanotic congenital heart disease ( CHD ) CDH may include study predetermine subgroup analysis ) cyanotic CHD transposition great artery ( TGA ) , total anomalous pulmonary venous return ( TAPVR ) , partial anomalous pulmonary venous return ( PAPVR ) , truncus arteriosus ( TA ) , tetralogy Fallot ( TOF ) , single ventricle physiology hypoplastic leave heart syndrome ( HLHS ) , tricuspid atresia , critical pulmonic stenosis atresia etc. , enrol conflict clinical trial ( randomize control blind trial another pulmonary vasodilator therapy ) ; Note : mother enrol fetal tracheal occlusion study FETO may enrol permit investigator fetal tracheal occlusion study ; [ FETO refers fetoscopic endoluminal tracheal occlusion involve occlusion fetal trachea balloon device midgestation subsequent removal later gestation ] infant bilateral CDH Note 3 : infant anterior central defect include study associate abnormality trachea esophagus ( tracheaesophageal fistula , esophageal atresia , laryngeal web , tracheal agenesis ) renal dysfunction ( serum creatinine &gt; 2 mg/dL due maternal factor ) severe oligohydramnios associate renal dysfunction randomization ; renal dysfunction may secondary renal anomaly medical condition acute tubular necrosis severe systemic hypotension ( mean blood pressure &lt; 35 mm Hg least 2 h vasoactive inotrope score &gt; 30 ) decision make provide comfort/ palliative care full treatment Intracranial bleed ( include follow finding cranial ultrasound ) Cerebral parenchymal hemorrhage Blood/echodensity ventricle distension ventricle Periventricular hemorrhagic infarction Posterior fossa hemorrhage Cerebellar hemorrhage persistent thrombocytopenia ( platelet count &lt; 80,000/mm3 ) despite blood product administration recent blood draw prior randomization coagulopathy ( PT INR &gt; 1.7 ) despite blood product administration recent blood draw ( checked reason check PT purpose study ) aneuploidy associate short life span ( trisomy 13 18 ) include study ( infant trisomy 21 include study ) elevate arterial , venous capillary PCO2 &gt; 80 mmHg spite maximal ventilator support ( include high frequency ventilation ) recent blood gas obtain within 12 hour prior randomization use milrinone infusion prior randomization ( use inhale pulmonary vasodilator iNO , inhaled epoprosternol , inhale PGE1 oral endothelin receptor antagonist permit Note : unlikely oral pulmonary vasodilator early course CDH ) ongoing therapy parenteral ( intravenous subcutaneous ) pulmonary vasodilator IV/SQ prostacyclin analog ( Epoprostenol Flolan Treprostinil Remodulin PGE1 Alprostadil ) IV phosphodiesterase 5 inhibitor ( sildenafil Revatio ) time randomization . In addition , initiation therapy two class parenteral medication first 24 hour study drug initiation permit consider protocol deviation . The risk systemic hypotension high first 24 hour studydrug ( milrinone ) infusion hence parenteral administration pulmonary vasodilator avoid minimize risk hypotension . Subjects already ECMO patient actively consider ECMO neonatal surgical team attending ( neonatal , critical care surgical ) refusal participation trial ( include concern presence hemodynamic instability )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>168 Hours</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CDH</keyword>
	<keyword>PPHN</keyword>
	<keyword>HRF</keyword>
</DOC>